A federal judge has laid bare how the 340B drug discount program, designed to help safety-net hospitals serve low-income patients, has become a vehicle for profit-driven institutions to undercut pharmaceutical companies while doing little to benefit the people the law was supposed to protect.
The ruling highlights how hospitals have weaponized the program to purchase drugs at steep discounts, then turn around and pocket the difference when they resell those same medications to insured patients at full retail prices. The spread between what hospitals pay and what they charge creates a windfall that rarely, if ever, reaches the vulnerable populations the program was created to serve.
What started as a Congressional effort to guarantee discounts for uninsured and low-income patients has metastasized into something far different. Large hospital systems have stretched eligibility rules to capture discounts on medications used across their entire patient populations, not just the vulnerable. This means a wealthy insured patient receiving cancer treatment at a participating hospital might be treated with drugs purchased at deep discounts, yet billed at rates that benefit the institution, not the patient.
Drug makers contend they've been systematically undercut by hospitals exploiting ambiguous regulations. Patients point out they see no relief at the pharmacy counter. Safety-net hospitals, meanwhile, argue they need the revenue to fund care for the uninsured. The disconnect between the program's intent and its execution has created a three-way standoff with no clear winners except the middlemen.
The judge's decision throws a spotlight on a program that has drifted so far from its moorings that reform appears inevitable. Whether Congress acts or regulators step in, the current model has become indefensible.
Author James Rodriguez: "This is what happens when a well-intentioned law meets aggressive accounting and nobody's watching the store."
Comments